SGEN News Alert Seattle Genetics (SGEN) 31.10 12/25/2014 09:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Seattle Genetics (SGEN) 31.10 $SGEN

5 Stocks Insiders Are Snapping Up: Seattle Genetics and More
at The Street - Wed Dec 24, 7:22AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
GLP: 34.90 (-0.19), SGEN: 31.10 (-0.14), HDS: 29.72 (+0.01), SJW: 32.40 (+0.28), PAH: 23.00 (+0.01)

Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger?
Cheryl Swanson - at Seeking Alpha - Tue Dec 23, 10:21AM CST

SGEN: 31.10 (-0.14), AGIO: 109.67 (+2.45), CELG: 109.60 (+3.48)

Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.10 (-0.14), ARWR: 6.35 (+0.07), ACHN: 13.06 (+1.22), SNSS: 2.48 (-0.03), ARRY: 4.64 (+0.07)

Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 10:20AM CST
Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
CYTK: 5.87 (+0.35), BIIB: 340.89 (+5.13), SGEN: 31.10 (-0.14), AMGN: 160.67 (+3.15)

Zacks' Bull Of The Day: Seattle Genetics
Zacks Investment Research - Seeking Alpha - Fri Dec 19, 8:14AM CST
Seattle Genetics (NASDAQ: SGEN ) is a $4 billion biotechnology company focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer. They are the industry leaders in antibody-drug conjugates (ADCs), a...
SGEN: 31.10 (-0.14)

Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Fri Dec 19, 12:00AM CST
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
PCYC: 121.84 (+1.15), SGEN: 31.10 (-0.14), INCY: 71.57 (+1.99), MRK: 57.46 (+0.25), AGIO: 109.67 (+2.45), BMY: 59.15 (-0.01)

Seattle Genetics: Good Tech, But On The Wrong Path
Owen Zeng - at Seeking Alpha - Thu Dec 18, 5:42PM CST

SGEN: 31.10 (-0.14)

Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia
Business Wire - Thu Dec 18, 8:00AM CST
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen. SGN-CD33A is a novel antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is also under evaluation in an ongoing phase 1 dose escalation trial as a single-agent or in combination with hypomethylating agents for the treatment of patients who have relapsed AML or have declined intensive frontline therapy.
SGEN: 31.10 (-0.14)

InsiderInsights.com Daily Round Up 12/17/14: HTZ, NAV, ENH, AIRT
InsiderInsights - at Seeking Alpha - Thu Dec 18, 3:35AM CST

CNXR: 8.90 (+0.15), HTZ: 24.38 (-0.09), ZSPH: 43.93 (+1.77), ISIG: 3.78 (+0.02), WMS: 23.00 (+0.28), AIRT: 24.17 (+0.03), MAR: 78.35 (-0.19), RL: 184.35 (+0.70), ADBE: 74.74 (+0.36), CI: 104.23 (-0.08), AMH: 17.34 (-0.07), WIW: 11.28 (+0.03), NOW: 69.69 (+0.12), SGEN: 31.10 (-0.14), BEAV: 58.63 (-0.02), NAV: 33.81 (-0.11), AGIO: 109.67 (+2.45), AI: 27.70 (-0.12), ENH: 59.60 (-0.55)

InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST

TRVN: 5.38 (-0.37), HSGX: 10.51 (-0.46), VR: 41.51 (+0.19), LBTYK: 49.10 (+0.05), ATLS: 30.37 (-0.07), UHS: 111.87 (+0.99), CLH: 49.40 (-0.60), WMS: 23.00 (+0.28), ALEX: 40.09 (+0.38), CDW: 35.75 (+0.14), BABY: 36.45 (+1.14), PRSS: 2.42 (-0.01), SGEN: 31.10 (-0.14), CO: 4.40 (+0.05), HBI: 110.93 (-0.07), TWI: 10.92 (-0.20), HSIC: 137.87 (+0.15), PSEC: 8.59 (-0.02), XLRN: 38.80 (+0.80)

Seattle Genetics Is Offering Growth, For A Price
Cory Renauer - at Seeking Alpha - Wed Dec 10, 12:06PM CST

SGEN: 31.10 (-0.14)

Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
Business Wire - Mon Dec 08, 6:30PM CST
--Phase 1b Combination Trial Planned to Evaluate SGN-CD33A with Standard of Care in Frontline and Consolidation Settings for Acute Myeloid Leukemia
SGEN: 31.10 (-0.14)

Seattle Genetics Presents ADCETRIS(R) (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting
Business Wire - Mon Dec 08, 6:30PM CST
---Phase 2 Randomized Trial Planned for Relapsed/Refractory CD30-Positive DLBCL-
SGEN: 31.10 (-0.14)

Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 4:10PM CST
Bristol-Myers Squibb Company (BMY) announced encouraging data from the ongoing phase Ib CheckMate - 039 study on Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), SGEN: 31.10 (-0.14), BMY: 59.15 (-0.01)

Seattle Genetics-Takeda's Adcetris Shows Long-Term Effect - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:20PM CST
Seattle Genetics, Inc. (SGEN) and Takeda announced four-year overall survival data from a pivotal phase II study on Adcetris for systemic anaplastic large cell lymphoma.
BIIB: 340.89 (+5.13), SGEN: 31.10 (-0.14), AMGN: 160.67 (+3.15)

Merck's New Oncology Product Positive in Early Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:10PM CST
Merck (MRK) announced encouraging early results from the ongoing phase Ib study on Keytruda.
AGN: 210.12 (+0.95), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)

Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST

SGEN: 31.10 (-0.14), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07)

Seattle Genetics Highlights Multiple ADCETRIS(R) (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
Business Wire - Mon Dec 08, 9:00AM CST
---ADCETRIS in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma as Second-line Therapy Shows Objective Response Rate of 96 Percent and Complete Remission Rate of 83 Percent-
SGEN: 31.10 (-0.14)

The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 88.76 (+3.23), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), SNSS: 2.48 (-0.03), AGIO: 109.67 (+2.45), BMY: 59.15 (-0.01), XLRN: 38.80 (+0.80), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 128

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 82

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading